5Jonsen A R, Siegler M, Winslade W J. Clinical ethics-a practical approach to ethical decisions in clinical medicine[M]. 4^th ed. New York:McGraw-Hill, 1998:12. 被引量：1
6DeMaagd G.High-risk drugs in the elderly population[J].Geriatr Nuts,1995,16(5):198-207. 被引量：1
7Gidal BE.Drug absorption in the elderly:biopharmaceutical considerations for the antiepileptic drugs[J].Epilepsy Res,2006,68(Suppl 1):S65-S69. 被引量：1
8Dettli L.Individualization of drug dosage in patients with renal disease[J].Med Clin North Am,1974,58 (5):977-985. 被引量：1
9Turnheim K.Drug dosage in the elderly.Is it rational[J]? Drugs Aging,1998,13(5):357-379. 被引量：1
10Beers MH.Explicit criteria for determining potentially inappropriate medication use by the elderly[J].Arch Intern Med,1997,157(14):1531-1536. 被引量：1
8Duursma S. Teaching and training in geriatric medicine in theEuropean Union [ J]. Tijdschrift voor Gerontologieen Geriatrie,2005,36(1):19-26. 被引量：1
9Politynska B,Van Rijsselt RJ,Lewko J. Quality assurance in gerontological and geriatric training programs:the European case[J].Gerontology and Geriatrics Education,2012,(01):39-54. 被引量：1
10Romero-Ortuno R. The Frailty Instrument of the Survey of Health,Ageing and Retirement in Europe (SHARE-FI) predicts mortality beyond age,comorbidities,disability,self-rated health,education and depression[J].Eur Geriatr Med,2011,(06):323-326. 被引量：1
